![Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response]()
Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of ResponseWong, N. S.; Buckman, R. A.; Clemons, M.; Verma, S.; Dent, S.; Trudeau, M. E.; Roche, K.; Ebos, J.; Kerbel, R.; DeBoer, G. E.; Sutherland, D. J.A.; Emmenegger, U.; Slingerland, J.; Gardner, S.; Pritchard, K. I. · Journal of Clinical Oncology · 2010